Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy
- 12 May 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 106 (19), 7957-7961
- https://doi.org/10.1073/pnas.0902857106
Abstract
The MAPK signal transduction cascade is dysregulated in a majority of human tumors. Here we report that a nanoparticle-mediated targeting of this pathway can optimize cancer chemotherapy. We engineered nanoparticles from a unique hexadentate-polyD,L-lactic acid-co-glycolic acid polymer chemically conjugated to PD98059, a selective MAPK inhibitor. The nanoparticles are taken up by cancer cells through endocytosis and demonstrate sustained release of the active agent, resulting in the inhibition of phosphorylation of downstream extracellular signal regulated kinase. We demonstrate that nanoparticle-mediated targeting of MAPK inhibits the proliferation of melanoma and lung carcinoma cells and induces apoptosis in vitro. Administration of the PD98059-nanoparticles in melanoma-bearing mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy. Our study shows the nanoparticle-mediated delivery of signal transduction inhibitors can emerge as a unique paradigm in cancer chemotherapy.Keywords
This publication has 23 references indexed in Scilit:
- The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel TherapeuticsJournal of Pharmaceutical Sciences, 2008
- Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung AdenocarcinomaCancer Research, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Temporal targeting of tumour cells and neovasculature with a nanoscale delivery systemNature, 2005
- Targeting of Mitogen-Activated Protein Kinases and Phosphatidylinositol 3 Kinase Inhibits Hepatocyte Growth Factor/Scatter Factor–Induced AngiogenesisCirculation, 2003
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in VivoOnline Journal of Public Health Informatics, 1995
- Prevalence of ras gene mutations in human colorectal cancersNature, 1987